undamentalytics Newsletter
Sign in

Medline Inc. (MDLN) stock

Add to watchlist

Add holding +

NASDAQ: MDLN Nasdaq Health Care Distributors Next results ~November 4, 2026

Medline Inc. is a US-listed company in the health care distributors industry. Its financial year ends in December.

Stock price today

Loading chart…

Third-party market data · may be delayed

Fair value per share

Under review: data-quality checks not passed.

Price vs value

Under review: data-quality checks not passed. We'll show the comparison once resolved.

Medline Inc. valuation: adjust assumptions and compare models →

Who’s trading

What company insiders, investment funds and members of Congress have been doing with the stock, from their own filings.

  • Insiders4 buying, 14 selling5 purchases and 41 sales by directors and officers, last 12 monthsInsider trades
  • Funds314 adding, 140 cuttingOf 82 active managers that changed their stake, 41 added; quarter to June 30, 2026Fund buyers and sellers

The Fundamentalytics view

Next results ~November 4, 2026 (estimated)

Current signal Results well ahead of expectations: Reported earnings per share beat the analysts' consensus estimate by 56% in the quarter to 2026-06-30, the 3rd beat in the last four quarters.

Assembled from SEC-filed figures — the full workings are on this page and in our methodology. Observations, not recommendations.

Highlights

How we pick these

Strengths

Nothing in Medline Inc.'s latest figures clears our strength thresholds.

Things to watch

  • Estimates being cut. Analysts' consensus for next year's earnings per share has fallen 5.7% over 90 days.

Latest results: FY2026 Q2

Filed August 5, 2026
Earnings per share
$0.50 against an average estimate of $0.32: beat by 55.8%
Revenue
$7.68bn, up 11.6% on a year earlier
Share reaction
-17.9% in the first session after the results on August 5, 2026, against -0.4% for the S&P 500
Guidance given
organic Sales growth growth 9% to 10% (full year 2026); adjusted EBITDA $3.3bn to $3.4bn (full year 2026)
Next report
November 4, 2026; average EPS estimate $0.35

Medline's figures from its SEC filings and results release; estimates are the analysts' average. Not a recommendation.

Price chart

  • 1 day+4.7%
  • 1 week-0.2%
  • 1 month-5.6%
  • This year-19.9%
  • S&P 500 this year+11.2%

Closing prices to 2026-11-02. Price change only, dividends excluded.

Loading chart…

Third-party market data · may be delayed

At a glance

Trailing twelve months, from SEC filings

Profitability

Revenue (TTM)
$27.4B
Operating margin
8.3%
Net margin
4.5%

Cash

Stock pay % of revenue
0.2%

Earnings

Last results
August 5, 2026

News & updates

Updated October 31, 2026

Company announcements, filed results and changes that matter to shareholders.

  1. Announcement
  2. Announcement
  3. Announcement
  4. Announcement
  5. Announcement
  6. Leadership
  7. Announcement
  8. Insider trade
  9. Insider trade
  10. Announcement
  11. Insider trade
  12. Insider trade
  13. Announcement
  14. Announcement
  15. Announcement
  16. Insider trade
  17. Insider trade
  18. Insider trade
  19. Insider trade
  20. Results
  21. Insider trade
  22. Guidance
  23. Leadership

Refreshed hourly when new source data is available. Summaries are checked against company releases and SEC filings. Company announcement headlines are labelled when a checked summary is unavailable.

Valuation

Medline Inc. valuation models and calculator

Fundamentalytics rating

model v1.6 · 2026-11-03

Not rated: data-quality checks not passed.

Valuation multiples over time Market data may be delayed

At fiscal year end 2025
Share price$42.00
Market value$34.0bn
+ Net debt (− = net cash)$10.8bn
Enterprise value$44.8bn
Multiples
Price / sales 1.2x
Price / earnings 29.5x
Price / free cash flow 26.2x
EV / EBITDA 13.9x

Market value uses the period's diluted share count; figures for each fiscal year use that year's results and the price at year end. "Now" uses today's price and the last twelve months.

Moat

Not assessed: fewer than five years of comparable figures in the filings. AI disruption exposure for this industry: Medium.

A rules-based reading of reported figures, not a forecast and not investment advice. How the score is built: methodology.

Forecasts and guidance

Next results: November 4, 2026, before the open. Analysts expect revenue of $7.7bn and EPS of $0.35 (range $0.28 to $0.47) for the quarter.

Analysts' consensus

Fiscal yearEPSGrowthRevenueGrowth
Current $1.54 +17% $31.2bn +10%
Next $1.57 +2% $33.7bn +8%

Next year's EPS estimate has moved −5.7% in 90 days, across 25 analysts.

How the EPS forecast has moved

The consensus EPS forecast for the current fiscal year is +1.5% on 90 days ago. In the last 30 days, 0 analysts raised Medline Inc.'s forecast and 2 cut it.

Consensus EPS forecast Medline Inc., last 90 days
$1.50 $1.55 $1.60 $1.65 $1.70 90 days ago 60 days ago 30 days ago 7 days ago Now Current fiscal year, 90 days ago: $1.51 Current fiscal year, 60 days ago: $1.57 Current fiscal year, 30 days ago: $1.55 Current fiscal year, 7 days ago: $1.54 Current fiscal year, Now: $1.54 $1.54 Next fiscal year, 90 days ago: $1.67 Next fiscal year, 60 days ago: $1.58 Next fiscal year, 30 days ago: $1.58 Next fiscal year, 7 days ago: $1.58 Next fiscal year, Now: $1.57 $1.57

Average of analysts' published estimates (third-party data).

View chart data
Period Current fiscal yearNext fiscal year
90 days ago $1.51$1.67
60 days ago $1.57$1.58
30 days ago $1.55$1.58
7 days ago $1.54$1.58
Now $1.54$1.57

Earnings against estimates

Quarter toEstimateActualSurprise
Jun 2026 $0.32 $0.50 +55.8%
Mar 2026 $0.29 $0.33 +12.2%
Dec 2025 $0.24 $0.31 +30.0%

Adjusted EPS as companies report it, against the average analyst estimate.

Management guidance

Earnings release, August 5, 2026
  • Organic Sales growth full year 2026 9% growth to 10% growth Non-GAAP Raised
    “The Company is updating its full year 2026 outlook for Organic Sales 2 growth to 9.0% to 10.0%, compared to its previous outlook of 8.5% to 9.5%, reflecting strong existing and new customer demand.” source
  • Adjusted EBITDA full year 2026 $3.3bn to $3.4bn Non-GAAP Lowered
    “The Company updated its Adjusted EBITDA 2 outlook to $3.3 billion to $3.4 billion, compared to its previous outlook of $3.5 to $3.6 billion, primarily reflecting higher than expected inflationary pressure from the Middle East conflict, increased operational investments to support customer demand, quality remediation efforts, and retail channel softness.” source

Figures and quotations are management's, copied from the company's own press release (SEC 8-K exhibit) and checked word for word against it. Forward-looking statements are the company's expectations, not ours and not advice; guidance can change or be missed.

Analyst recommendations

27 analysts, Oct 2026
Buy2385%
Hold415%
Sell00%

Monthly trend

  1. Oct 2026716427
  2. Sep 2026716427
  3. Aug 2026716427
  4. Jul 2026716427

Counts of recommendations published by analysts covering Medline Inc., by month. Source: Aggregated broker recommendations (third-party data). Aggregated counts only: we do not reproduce any firm's recommendation or price target, and these are not Fundamentalytics ratings.

Positioning

Short interest
9.7%
of tradable shares
Days to cover
4.51
at average volume
Short interest, 1 month
−1%
to October 15, 2026
Held by institutions
—
of shares
Held by insiders
0.3%
of shares
Employees
45,000
full time

Consensus figures average analysts' published estimates (third-party data); guidance is the company's own. Neither is our forecast. Short interest is reported twice a month and lags. Market data may be delayed.

This section is general information, not investment advice or a personal recommendation, and it does not take account of your objectives or circumstances. Forecasts and guidance are estimates, not promises: companies miss their own guidance and analysts' figures are often revised. Prices can fall as well as rise, and you can lose money. See our disclaimer.

Share-price performance

Market data may be delayed

Return and risk by year

Calendar year 2026 to date
Return
MDLN−20%
Industry peers (median)+8%
S&P 500+11%
Months that ended higher
MDLN36%
S&P 50046%
Largest fall from a high during the year
MDLN−37%
S&P 500−9%

Worst fall since December 17, 2025: 37% from February 24, 2026 to September 18, 2026. Getting back needed a 58% gain, and the shares have not yet recovered.

Price behaviour

52-week range
Not enough history
From 52-week high
—
vs 50-day average
−2.5%
vs 200-day average
−15.1%
Volatility (1 year)
44%
Beta vs S&P 500
0.55

Volatility is the annualised standard deviation of daily returns. Beta 1.5 means the shares typically moved 1.5% for each 1% move in the S&P 500 over the past year. Prices to November 2, 2026.

Share price after results

Next day
0 up, 3 down
typical move ±9.2%
After a week
0 up, 3 down
typical move ±14.8%
After a month
0 up, 3 down
typical move ±18.1%
Results releasedNext dayS&P 500 next day5 days21 days
August 5, 2026 −17.9% −0.4% −15.6% −13.0%
May 6, 2026 −7.6% +1.1% −14.6% −25.8%
February 25, 2026 −2.2% +0.3% −14.2% −15.6%

From the close before the release date to the close 1, 5 and 21 trading days after it, so releases before the open and after the close are both captured. Past moves don't predict future ones.

Fundamentals

Data: SEC EDGAR XBRL company facts (as filed in 10-K/10-Q); forms 10-K, 10-Q, 424B4. Generated November 3, 2026. Definitions in our methodology.

Where the money goes

FY2025, from the 10-K

Each dollar Medline took in during FY2025, followed through to profit: what it cost to make, what went on running the business, and what was left after tax.

  1. Revenue $28.4B
  2. Cost of revenue $20.9B · 73.6%
  3. Gross profit $7.5B · 26.4%
  4. Selling, general and admin $4.5B · 15.9%
  5. Other operating costs $702M · 2.5%
  6. Operating income $2.2B · 7.8%
  7. Interest and other $968M · 3.4%
  8. Net income $1.2B · 4.1%

Shares of revenue. Source: Medline's 10-K for FY2025, as filed with the SEC. "Other" lines are what the reported lines leave unexplained.

Financial statements

US$ billions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year 2022 Dec 2022 2023 Dec 2023 2024 Dec 2024 2025 Dec 2025
Income
Revenue 21.4 23.2 25.5 28.4
Gross profit 5.2 5.9 7.0 7.5
EBITDA — 2.2 3.1 3.2
Operating income 0.9 1.3 2.1 2.2
Net income −0.0 0.2 1.2 1.2
Diluted EPS — — — −$0.01
Growth (year on year)
Revenue — +8.3% +9.8% +11.5%
EBITDA — — +41.9% +3.2%
Operating income — +45.2% +71.7% +3.1%
Net income — — — −0.9%
Margins
Gross margin 24.3% 25.3% 27.3% 26.4%
EBITDA margin — 9.5% 12.2% 11.3%
Operating margin 4.0% 5.4% 8.4% 7.8%
Net margin −0.1% 1.0% 4.6% 4.1%
Free-cash-flow margin — 6.1% 5.5% 4.6%
Cash flow
Cash from operations 0.2 1.7 1.8 1.7
Capital spending — 0.3 0.4 0.4
Free cash flow — 1.4 1.4 1.3
Stock-based pay 0.1 0.1 0.1 0.1
Free cash flow after stock pay — 1.3 1.4 1.2
Balance sheet
Cash 0.4 1.6 0.2 1.9
Total debt 0.0 0.0 16.8 12.8
Net debt (negative = net cash) −0.4 −1.6 16.6 10.8
Diluted shares — — — 810m
Returned to shareholders
Buybacks — 0.0 0.0 0.0
Total returned — 0.0 0.0 0.0

Source: SEC EDGAR XBRL company facts (US and foreign periodic filings); column headings link to the filing. EBITDA is operating income plus depreciation and amortisation. Free cash flow is cash from operations minus capital spending. Growth is left blank when last year's figure was a loss or under 2% of revenue. Share counts and EPS are restated for stock splits. A dash means the company didn't report the figure.

Financial health

1 of 4 checks passed · June 27, 2026
What it owns · $39.4bn
Short-term assets $11.7bnLonger-term assets $27.6bn
What it owes, and who funded it · $31.8bn
Short-term liabilities $2.7bnLonger-term liabilities $17.6bnShareholders' equity $11.6bn
  • Short-term assets cover short-term liabilities $11.7bn of assets due within a year against $2.7bn of liabilities due within a year.
  • Short-term assets cover long-term liabilities $11.7bn short-term assets against $17.6bn of longer-dated liabilities.
  • More cash than debt $2.3bn of cash against $12.6bn of debt.
  • Debt below 40% of shareholders' equity Debt is 109% of equity.
  • Debt burden no higher than five years ago Five-year comparison not available. Not assessable.
  • A year's operating cash flow covers at least 20% of debt Cash flow or debt not reported. Not assessable.
  • Operating profit covers interest at least five times over Interest not separately reported. Not assessable.

From Medline Inc.'s latest balance sheet as filed. Checks are fixed, documented rules (methodology), counted only where the company reports the figures — a dot means the filing doesn't break the item out. Descriptions of reported data, not advice.

Dividends, buybacks and capital spending

Buybacks, last 3 fiscal years
$53M

Competitors: side by side with peers

Closest by revenue in health care distributors
Last 12 months unless stated MDLN HSIC COR MCK YI COSM Median
Revenue, last 12 months $27.4bn $13.6bn $332.8bn $411.0bn $1.7bn $74m $13.6bn
Revenue growth, last 12 months — 6.5% 5.1% 8.8% −12.7% 33.8% 5.8%
Revenue growth, 3-year average — 2.6% 9.4% 13.1% — 14.8% 11.2%
Revenue growth, latest quarter 11.6% 6.7% 5.1% 7.7% — 28.8% 7.7%
Gross margin 27.2% 31.3% 4.0% 3.6% 5.8% 10.3% 10.3%
Operating margin 8.3% 5.0% 0.9% 1.6% −0.0% −24.9% 0.9%
Operating margin, 3-year average — 4.8% 0.9% 1.3% −10.6% −29.5% 0.9%
Net margin 4.5% 3.0% 0.8% 1.1% −0.5% −33.1% 0.8%
Cash from operations / revenue 5.3% 5.1% 1.4% 1.7% 0.9% −13.3% 1.4%
Free-cash-flow margin — 4.2% 1.2% 1.6% 0.9% −13.5% 1.1%
Free-cash-flow margin, 3-year average — 3.8% 1.0% 1.4% −9.0% −12.4% 1.0%
Stock pay / revenue 0.2% 0.3% 0.0% 0.1% 0.1% 2.3% 0.1%
Change in share count — −6.1% −0.5% −3.4% 1.3% 79.3% 0.4%

Median of all 7 companies we cover in health care distributors. Shaded: best of the six on that line (lowest for stock pay and share-count growth). 3-year figures average the last three 12-month periods; 3-year growth is compound annual. Source: SEC filings.

Where the revenue comes from

Fiscal year to December 31, 2025
Geography
Region Revenue Share YoY
United States $26.5B 93.1% ▲ 11.5%
Outside the US $2B 6.9% ▲ 11.0%

From Medline Inc.'s 10-K filed February 25, 2026, as tagged in the filing. View filing. Indented rows are part of the line above; their share is of that line. In the bars, the faint bar behind is the year before.

Who owns it

Funds buying and selling
Reported value
$29.6B
Institutions reporting
402
Shares held vs prior quarter
▲ 17.9%
Positions opened / closed
159 / 75

Top buyers and sellers, Q2 2026: 314 institutions bought and 140 sold ; the biggest buyer was Invesco Ltd (+17.4M shares) and the biggest seller H&F Corporate Investors X, Ltd (−15.6M). See which funds bought and sold →

Largest reported holders, June 30, 2026
Manager Value Shares Share of 13F value Shares QoQ
Carlyle Group Inc. $7.4B 187.1M 24.9% 0.0%
H&F Corporate Investors X, Ltd. $2.8B 70.9M 9.4% ▼ 18.0%
FMR LLC $1.9B 47.0M 6.3% ▲ 28.5%
Capital Research Global Investors $1.6B 40.0M 5.3% ▲ 72.5%
Invesco Ltd. $1.5B 38.3M 5.1% ▲ 82.9%
Blackrock, Inc. $1B 26.4M 3.5% ▲ 56.0%
Morgan Stanley $852M 21.6M 2.9% ▲ 37.6%
Lone Pine Capital LLC $827M 21.0M 2.8% ▲ 77.9%
Massachusetts Financial Services Co $787M 19.9M 2.7% ▲ 71.9%
Vanguard Capital Management LLC $703M 17.8M 2.4% ▲ 21.0%
Vanguard Portfolio Management LLC $662M 16.8M 2.2% ▲ 18.6%
Egerton Capital (UK) LLP $650M 16.5M 2.2% ▲ 277.3%

From Form 13F filings with the SEC ( quarterly data sets), as reported by each manager for June 30, 2026 and filed up to 45 days later. 13F reports cover long US-listed positions of managers above $100M only, so this is not Medline Inc.'s complete shareholder register. Values are as reported by the filers ; 1 inconsistently scaled filing rows were excluded.

Insider trading activity

Full insider history and chart
Insider purchases History → $515M 5 trades by 4 insiders, last 12 months Insider sales History → $12.1B 41 trades by 14 insiders · 0% under pre-set plans
Net ▼ $11.6B net selling
Insider Date Trade Shares Price Value
Gic Private Ltd 10% owner October 8, 2026 Sell 7,816,987 $35.15 $275M
Gic Private Ltd 10% owner October 6, 2026 Sell 7,183,013 $35.05 $252M
Gic Private Ltd 10% owner October 6, 2026 Sell 2,088,987 $35.05 $73.2M
Gic Private Ltd 10% owner October 5, 2026 Sell 1,688,690 $35.78 $60.4M
Gic Private Ltd 10% owner October 2, 2026 Sell 7,146,941 $34.33 $245M
Gic Private Ltd 10% owner October 2, 2026 Sell 2,570,999 $35.35 $90.9M
Hux Investment Pte. Ltd. 10% owner August 14, 2026 Sell 100,000 $35.80 $3.6M
Hux Investment Pte. Ltd. 10% owner August 13, 2026 Sell 1,500,000 $35.80 $53.7M
Gic Private Ltd 10% owner August 7, 2026 Sell 590,284 $35.58 $21M
Hux Investment Pte. Ltd. 10% owner August 6, 2026 Sell 271,994 $35.33 $9.6M
Hux Investment Pte. Ltd. 10% owner August 5, 2026 Sell 1,710,907 $35.46 $60.7M
Hux Investment Pte. Ltd. 10% owner August 5, 2026 Sell 265,711 $36.48 $9.7M

From insiders' Form 4 filings with the SEC. Excludes awards, option exercises and shares withheld for tax. "Pre-set plan" means the filing marks the trade as made under a Rule 10b5-1 plan. See every insider trade since five years ago, on a price chart.

Earnings dates and SEC filings

Results announcements

Next expected around October 26, 2026 estimated from the company's past filing pattern, not announced

  • August 5, 2026
  • May 6, 2026
  • February 25, 2026

Recent SEC filings

Data status

When each part of this page on Medline Inc. was last updated.

DataLast updatedSource
Share priceExchange closing prices
Financial statementsSEC 10-K and 10-Q filings
News and updatesCompany releases and SEC 8-K filings
Analyst estimatesAggregated analyst estimates
Valuation and scoresOur models, from the filed figures

How we build and check these figures: methodology and data sources.

Medline Inc. in brief

What does Medline Inc. do?
Medline Inc. is a US-listed company in the health care distributors industry. Its financial year ends in December.
What is Medline Inc.'s stock ticker?
Medline Inc. trades under the ticker MDLN on Nasdaq. This page brings together its financial statements, valuation models, ownership and recent company updates.
Who are Medline Inc.'s largest institutional shareholders?
By value reported in 13F filings for June 30, 2026, the largest reported holders are Carlyle Group Inc., H&F Corporate Investors X, Ltd. and FMR LLC. 13F reports cover long US-listed positions of managers above $100M, filed up to 45 days after quarter end.
What is Medline Inc.'s market cap?
On December 31, 2025, Medline Inc.'s market capitalisation was about $34B, with a price-to-earnings ratio of 29.5 and net debt of $10.8B. Market figures come from third-party market data and may be delayed.
How much debt does Medline Inc. have?
Medline Inc.'s debt-to-equity ratio is 108.7%, from its latest balance sheet. The financial health section below sets out its other solvency checks.
Who are Medline Inc.'s competitors?
In our Health Care Distributors peer group, the companies closest to Medline Inc. are Henry Schein, Cencora, McKesson, 111, Inc. and Cosmos Health Inc. The side-by-side comparison below sets their revenue, margins and growth against Medline Inc.'s.
Are insiders buying or selling Medline Inc. stock?
Over the last 12 months, Medline Inc.'s directors and officers reported 5 open-market purchases and 41 sales on Form 4. The insider trading page charts every trade.
When is Medline Inc.'s next earnings date?
Around November 4, 2026, estimated from the spacing of its past results announcements (8-K filings). That is an estimate, not a confirmed date — Medline Inc. announces its own schedule.